Ardelyx, Inc. (ARDX) Earnings Call Analysis

NASDAQ · Healthcare · Biotechnology

Earnings Reports

• Ardelyx (ARDX) Q1 2026: Ibsrella Revenue Jumps 58% as Specialty Channel Drives Prescription Fulfillment
  May 01, 2026
• Ardelyx (ARDX) Q4 2025: Ibsrella Surges 73% as Pipeline and IP Expansion Anchor $1B Ambition
  February 24, 2026
• Ardelyx (ARDX) Q3 2025: Ibsrella Surges 92% as Pipeline and Cash Position Reinvigorate Growth Ambitions
  October 31, 2025
• Ardelyx (ARDX) Q2 2025: Ibsrella Net Sales Surge 84% as Field Execution Drives Guidance Raise
  August 05, 2025
• Ardelyx (ARDX) Q1 2025: Absrella Revenue Jumps 57% as Field Expansion Drives IBSC Momentum
  July 04, 2025
• Ardelyx (ARDX) Q3 2024: Exposa Sales Jump 39% as Medicare Bundle Uncertainty Intensifies
  October 31, 2024
• Ardelyx (ARDX) Q2 2024: Exposa Revenue Surges 145%, Raising Stakes in Medicare Access Fight
  August 01, 2024
• Ardelyx (ARDX) Q1 2024: Exposa Launch Delivers $15.2M as Nephrology Adoption Accelerates
  May 02, 2024
• Ardelyx (ARDX) Q4 2023: Ibsrella Sales Up 26% QoQ, Fueling $140M+ 2024 Outlook
  February 22, 2024

Browse all companies